AsianScientist (May 8, 2014) – WuXi PharmaTech Inc., a pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, has broken ground on a new facility in Philadelphia for the manufacture of cell therapies. The facility is expected to become operational in the second quarter of 2015.
The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi’s existing 16,000-square-foot cGMP cell therapy manufacturing facility. It will be built using advanced modular design, with flexible clean room technology, disposable equipment, and microcarrier cell culture systems.
Located in the Philadelphia Navy Yard, the new facility will support growing customer demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics. It will also complement WuXi’s existing facility and capabilities which include analytical chemistry, cell banking, cell characterization, molecular biology and lot release testing, thereby providing fully integrated services for cell therapies in Philadelphia.
“Cell therapies offer important treatment options, and WuXi is committed to bringing them to patients faster,” said Dr. Ge Li, Chairman and CEO of PharmaTech.
——
Source: WuXi AppTech.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
